Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood bicarbonate levels may predict feeding issues in ICU patients

NCT ID NCT07518095

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will check if low bicarbonate levels in the blood can predict when adult ICU patients will have trouble with tube feeding. Researchers will watch 70 patients for 72 hours after they start feeding. The goal is to find a simple way to identify patients at risk, so doctors can act early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients aged 18 and older who are admitted to the intensive care unit (ICU). This group specifically includes those who begin enteral nutrition (EN) within the first 48 hours of their ICU admission and are expected to remain in the unit for at least 72 hours. The target sample size is 70 participants, factoring in potential drop-outs to maintain statistical power. Certain clinical conditions are excluded to ensure data consistency, such as pregnancy, 18 years of age or younger, active gastrointestinal bleeding or perforation, and recent major abdominal surgery. Additionally, patients requiring specialized enteral formulas or those with advanced organ failure (e.g., Child-Pugh C liver failure or dialysis-dependent kidney failure) are not included in the study population.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients aged 18 and older. * Patients started on enteral nutrition (EN) within the first 48 hours of their intensive care unit admission. * Patients predicted to remain in the intensive care unit for at least 72 hours. * Patients (or their legal representatives) who have provided consent to participate in the study. Exclusion Criteria: * Patients under the age of 18.Individuals who are currently pregnant or breastfeeding. * Patients with gastrointestinal (GI) perforation, active GI bleeding, or mechanical bowel obstruction. * Patients who have undergone major abdominal surgery (e.g., esophagectomy, gastrectomy) within the last month. * Patients receiving total parenteral nutrition (TPN) or those who are only fed orally. * Patients requiring specialized enteral formulas (e.g., diabetic, renal, immunomodulatory, elemental, or semi-elemental) due to clinical necessity. * Patients with a known diagnosis of diabetes or those with HbA1c \>6.5 requiring a diabetic enteral formula. * Patients with terminal-stage malignancy or those requiring specific enteral nutrition protocols. * Patients with advanced (Child-Pugh C) liver failure. * Patients with chronic kidney failure requiring dialysis. * Patients with diabetic ketoacidosis, severe metabolic asidozis, or those requiring initial bicarbonate replacement. * Patients who are brain dead or in the palliative care stage.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Enteral nutrition intolerance (EFI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istinye Üniversity

    Istanbul, Merkez Mahallesi, 34250, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.